Health-Chem Corporation (HCLC)
Health-Chem Corporation operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Emigsville, PA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $73,985. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -27.9%. Its beta of -26.02 implies it has historically moved less than the broad market.
Health-Chem Corporation, operating through its subsidiary, Transderm Laboratories Corporation, specializes in the research, development, manufacturing, and commercialization of transdermal drug delivery systems throughout the United States. Among its key products are transdermal nitroglycerin patches, formulated to provide relief for vascular and cardiovascular symptoms linked to angina pectoris (commonly known as chest pain) via skin absorption. The company additionally offers contract research and development services to third-party clients. Health-Chem Corporation employs a multifaceted sales strategy, directly engaging with wholesalers, distributors, prominent retail pharmacy chains, mail-order pharmacies, and group purchasing organizations. Its products also reach the market indirectly through independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit management firms. Founded in 1970, the company's headquarters are situated in Emigsville, Pennsylvania.
Health-Chem Corporation is most often compared with the following Healthcare names: